Limits...
TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.

Chen Z, Guo J, Zhang K, Guo Y - Dis. Markers (2016)

Bottom Line: However, the results were controversial.The risk ratio (RR) with a 95% confidence interval (95% CI) was calculated to assess the effect of TP53 mutations on 2-year overall survival.These data suggested that TP53 mutations had an unfavorable impact on 2-year overall survival when compared to the counterparts with wild type (WT) TP53 (RR: 1.79; 95% CI: 1.12 to 2.84; P = 0.01; I (2) = 0%).

View Article: PubMed Central - PubMed

Affiliation: Luoyang Orthopedic Hospital of Henan Province, Luoyang 471000, China.

ABSTRACT
Several research groups have examined the association between TP53 mutations and prognosis in human osteosarcoma. However, the results were controversial. The purpose of this study was to evaluate the prognostic value of TP53 mutations in osteosarcoma patients. A meta-analysis was conducted with all eligible studies which quantitatively evaluated the relationship between TP53 mutations and clinical outcome of osteosarcoma patients. Eight studies with a total of 210 patients with osteosarcoma were included in this meta-analysis. The risk ratio (RR) with a 95% confidence interval (95% CI) was calculated to assess the effect of TP53 mutations on 2-year overall survival. The quantitative synthesis of 8 published studies showed that TP53 mutations were associated with 2-year overall survival in osteosarcoma patients. These data suggested that TP53 mutations had an unfavorable impact on 2-year overall survival when compared to the counterparts with wild type (WT) TP53 (RR: 1.79; 95% CI: 1.12 to 2.84; P = 0.01; I (2) = 0%). There was no between-study heterogeneity. TP53 mutations are an effective prognostic marker for survival of patients with osteosarcoma. However, further large-scale prospective trials should be performed to clarify the prognostic value of TP53 mutations on 3- or 5-year survival in osteosarcoma patients.

No MeSH data available.


Related in: MedlinePlus

The flow chart of the included studies.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4863100&req=5

fig1: The flow chart of the included studies.

Mentions: In this study, we first searched PubMed, Embase, Web of Science, and CNKI databases, and a total of 674 published articles were reviewed using the search strategy as described above. As shown in Figure 1, we initially excluded 649 publications: 423 were of other diseases; 85 were animal experiments; 78 were not for TP53; 57 were comments or reviews, and 6 were case reports. By further review of the remaining 25 literatures, 16 publications were excluded due to lack of detailed survival analysis, and 1 was excluded because of overlapping with other studies. Finally, 8 studies were included in this meta-analysis [12, 13, 23–28].


TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.

Chen Z, Guo J, Zhang K, Guo Y - Dis. Markers (2016)

The flow chart of the included studies.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4863100&req=5

fig1: The flow chart of the included studies.
Mentions: In this study, we first searched PubMed, Embase, Web of Science, and CNKI databases, and a total of 674 published articles were reviewed using the search strategy as described above. As shown in Figure 1, we initially excluded 649 publications: 423 were of other diseases; 85 were animal experiments; 78 were not for TP53; 57 were comments or reviews, and 6 were case reports. By further review of the remaining 25 literatures, 16 publications were excluded due to lack of detailed survival analysis, and 1 was excluded because of overlapping with other studies. Finally, 8 studies were included in this meta-analysis [12, 13, 23–28].

Bottom Line: However, the results were controversial.The risk ratio (RR) with a 95% confidence interval (95% CI) was calculated to assess the effect of TP53 mutations on 2-year overall survival.These data suggested that TP53 mutations had an unfavorable impact on 2-year overall survival when compared to the counterparts with wild type (WT) TP53 (RR: 1.79; 95% CI: 1.12 to 2.84; P = 0.01; I (2) = 0%).

View Article: PubMed Central - PubMed

Affiliation: Luoyang Orthopedic Hospital of Henan Province, Luoyang 471000, China.

ABSTRACT
Several research groups have examined the association between TP53 mutations and prognosis in human osteosarcoma. However, the results were controversial. The purpose of this study was to evaluate the prognostic value of TP53 mutations in osteosarcoma patients. A meta-analysis was conducted with all eligible studies which quantitatively evaluated the relationship between TP53 mutations and clinical outcome of osteosarcoma patients. Eight studies with a total of 210 patients with osteosarcoma were included in this meta-analysis. The risk ratio (RR) with a 95% confidence interval (95% CI) was calculated to assess the effect of TP53 mutations on 2-year overall survival. The quantitative synthesis of 8 published studies showed that TP53 mutations were associated with 2-year overall survival in osteosarcoma patients. These data suggested that TP53 mutations had an unfavorable impact on 2-year overall survival when compared to the counterparts with wild type (WT) TP53 (RR: 1.79; 95% CI: 1.12 to 2.84; P = 0.01; I (2) = 0%). There was no between-study heterogeneity. TP53 mutations are an effective prognostic marker for survival of patients with osteosarcoma. However, further large-scale prospective trials should be performed to clarify the prognostic value of TP53 mutations on 3- or 5-year survival in osteosarcoma patients.

No MeSH data available.


Related in: MedlinePlus